SAMN47221435
External Id
dbGaP
INSDC center name
2025-03-05T06:03:51.607Z
INSDC first public
2025-04-26T20:31:44.837Z
INSDC last update
live
INSDC status
Generic
NCBI submission model
Generic.1.0
NCBI submission package
DNA/RNA
analyte type
NCI_NSCLC_RefractoryPDL1Therapy
biospecimen repository
CNTZHP5BP.01
biospecimen repository sample id
Tumor Tissue
body site
phs003295
gap_accession
1
gap_consent_code
DS-CA
gap_consent_short_name
7556319
gap_sample_id
5607304
gap_subject_id
Yes
is tumor
Homo sapiens
http://purl.obolibrary.org/obo/NCBITaxon_9606
organism
male
sex
Clinical Trial
study design
Durvalumab Plus Tremelimumab Alone or in Combination with Low-Dose or Hypofractionated Radiotherapy in Metastatic Non-Small-Cell Lung Cancer Refractory to Previous PD(L)-1 Therapy: an Open-Label, Multicentre, Randomised, Phase 2 Trial
study name
CNTZHP5BP.01
submitted sample id
CNTZHP5
submitted subject id
NCI_NSCLC_RefractoryPDL1Therapy
submitter handle
Tumor DNA/RNA sample from Tumor Tissue of a human male participant in the dbGaP study "Durvalumab Plus Tremelimumab Alone or in Combination with Low-Dose or Hypofractionated Radiotherapy in Metastatic Non-Small-Cell Lung Cancer Refractory to Previous PD(L)-1 Therapy: an Open-Label, Multicentre, Randomised, Phase 2 Trial"
title